Cohance Lifesciences Limited vs Eris Lifesciences Limited
Last updated: 27 October 2026
MoneyDock presents a comparative analysis between Cohance Lifesciences Limited (COHANCE.NS) and Eris Lifesciences Limited (ERIS.NS). Both companies operate within India's dynamic pharmaceutical and healthcare sectors, making them relevant for investors looking at the domestic healthcare market. While specific business models may vary, a comparison of their stock performance and fundamental metrics can offer valuable insights into their current market positioning and potential for future growth. Understanding their individual strengths and weaknesses is crucial for investors aiming to make informed decisions in this competitive industry.
Key Financial Metrics Comparison
| Metric | Cohance Lifesciences Limited | Eris Lifesciences Limited |
|---|---|---|
| Current Price | ₹479.25 | ₹1198.40 |
| 52-Week High | ₹539.85 | ₹1571.60 |
| 52-Week Low | ₹279.90 | ₹1095.50 |
| 1-Year Return | -10.99% | -23.75% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When evaluating Cohance Lifesciences and Eris Lifesciences, the available data highlights a few key differences. Both companies currently lack a Trailing P/E ratio and Market Cap data, which limits a direct valuation comparison based on these common metrics. However, we can still derive insights from their price movements and returns.
Valuation: Without P/E ratios or market capitalization, a definitive statement on which company offers better 'valuation' is challenging. Eris Lifesciences has a significantly higher current price at ₹1198.40 compared to Cohance Lifesciences at ₹479.25. This higher price point alone doesn't indicate over or undervaluation but suggests Eris is a more expensive stock in absolute terms.
Returns: In terms of 1-Year Returns, Cohance Lifesciences shows a return of -10.99%, while Eris Lifesciences has a more substantial negative return of -23.75%. This indicates that Cohance has performed relatively better over the past year, experiencing a smaller decline in value compared to Eris. For investors focused on recent performance, Cohance appears to have offered better capital preservation.
Stability: To gauge stability, we can look at the proximity of their current prices to their 52-week highs and lows. Cohance Lifesciences' current price of ₹479.25 is closer to its 52-week high of ₹539.85 than its 52-week low of ₹279.90. This suggests it has maintained more of its peak value compared to its floor. Eris Lifesciences, with a current price of ₹1198.40, is also closer to its 52-week low of ₹1095.50 than its 52-week high of ₹1571.60. This indicates Eris is currently trading nearer to the lower end of its annual range, which could be interpreted as a period of higher volatility or downward pressure. From this perspective, Cohance appears to exhibit relatively better price stability within its annual range.
MoneyDock Verdict
For Aggressive Investors: Given the limited data, particularly the absence of P/E and Market Cap, aggressive investors might see Cohance Lifesciences' smaller 1-year decline (-10.99% vs -23.75%) and current price being closer to its 52-week high as a sign of relative strength in a challenging market. However, with both stocks showing negative returns, aggressive investors might seek more comprehensive data or look for stronger growth catalysts.
For Conservative Investors: Both companies have shown negative 1-year returns, which typically deters conservative investors. However, if forced to choose based on the provided data, Cohance Lifesciences, with its less severe decline and current price indicating better retention of its annual peak, might be perceived as having slightly less downside risk compared to Eris Lifesciences. The lack of valuation metrics makes any investment inherently speculative for this profile.
For Long-Term SIP Investors: For long-term SIP investors, the current negative returns could present an opportunity for rupee cost averaging if they believe in the long-term prospects of either company. Cohance's milder decline in the past year might make it a marginally more attractive option for averaging down, assuming future recovery. However, the absence of fundamental valuation metrics like P/E and Market Cap is a significant hurdle. Long-term SIP investors should seek additional financial statements and business outlooks before committing.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.